글로벌 암 지원 케어 제품 시장 – 2031년까지의 산업 동향 및 예측

암 지원 케어 제품 시장 분석 및 규모

암 지지 치료 제품 시장은 환자의 삶의 질을 개선하는 것을 목표로 하는 혁신적인 기술과 방법으로 계속 발전하고 있습니다. 최근의 개발은 개인화된 치료, 표적 치료 및 치료 부작용을 완화하는 지지 치료 솔루션에 중점을 두고 있습니다. 이 시장은 의료 서비스 제공자가 포괄적인 암 치료를 우선시하고 지지 치료를 통합하여 환자의 결과와 웰빙을 향상시키면서 성장할 준비가 되었습니다.          

예를 들어, 세계 암 연구 기금 국제(WCRF)에 따르면, 비흑색종 피부암을 제외하고 2035년까지 전 세계적으로 2,400만 건 이상의 암 사례가 발생할 것으로 예측됩니다. 2017년 미국 국립암연구소(NIH)는 미국에서 150만 건 이상의 새로운 암 진단을 보고했습니다.                     

글로벌 암 지원 관리 제품 시장 규모는 2023년에 211억 4천만 달러로 평가되었으며, 2031년까지 257억 6천만 달러에 도달할 것으로 예상되며, 2024년부터 2031년까지 예측 기간 동안 CAGR은 2.5%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

Market Definition

Cancer supportive care products encompass a range of treatments and aids designed to alleviate symptoms and side effects associated with cancer and its treatments. These include medications for pain management, anti-nausea drugs, wound care supplies, nutritional supplements, and psychological support tools. Their aim is to enhance the quality of life for cancer patients by addressing physical, emotional, and practical challenges during their treatment journey.           

Cancer Supportive Care Products Market Dynamics

Drivers

• Increasing Cancer Incidence

The increasing global incidence of cancer has spurred a heightened demand for supportive care products that alleviate treatment-related symptoms and side effects. For instance, medications addressing chemotherapy-induced nausea and pain management therapies have become essential in enhancing patient comfort and treatment adherence. This rising necessity underscores the market's growth as healthcare providers and patients prioritize comprehensive supportive care to improve quality of life during cancer treatment.

• Rising Focus on Patient-Centric Care

The rising focus on patient-centric care models is significantly driving the growth of the cancer-supportive care products market. Healthcare providers increasingly integrate comprehensive supportive care into cancer treatment plans, enhancing patient comfort and quality of life. For instance, programs offering integrated supportive care services, such as pain management, nutrition counseling, and psychological support alongside chemotherapy or radiation therapy, demonstrate the market's responsiveness to patient needs and preferences, thereby expanding market opportunities.

Opportunities

• Supportive Government Initiatives and Healthcare Policies

Supportive government initiatives and healthcare policies create significant opportunities for the cancer supportive care products market by encouraging their adoption and integration into standard care protocols. For instance, policies that subsidize or reimburse costs associated with supportive care products, such as pain management medications or nutritional supplements, can lower barriers to access. This not only enhances patient outcomes but also expands market potential in regions where such policies are implemented effectively.

• Advancements in Cancer Therapies

Technological advancements in cancer therapies, such as targeted therapies and immunotherapies, have significantly improved treatment outcomes. However, these treatments often bring side effects such as nausea, fatigue, and neuropathy. This creates opportunities in the market for supportive care products such as anti-nausea medications, pain relievers, and nutritional supplements. For instance, the development of novel antiemetic drugs has addressed chemotherapy-induced nausea, enhancing patient comfort and quality of life during treatment.

Restraints/Challenges

• Adverse Effects and Safety Concerns

Adverse effects and safety concerns associated with supportive care products in cancer treatment often hinder market adoption. Balancing the benefits of symptom relief with potential risks requires rigorous evaluation and monitoring. Concerns over side effects can deter healthcare providers and patients from using these products, impacting their market penetration and acceptance despite their intended therapeutic benefits. 

• Complexity of Clinical Trials

The complexity of clinical trials for cancer supportive care products is hindered by diverse patient populations and subjective endpoints such as quality of life. These factors contribute to prolonged development and approval timelines, slowing market entry. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In March 2022, Imugene, an Australian biotech company, announced a collaboration with MSD (Merck & Co., Inc.) to assess HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD's pembrolizumab (KEYTRUDA) for HER-2 positive gastric cancer patients. The clinical trial aims to evaluate the safety and efficacy of this combination therapy
• In March 2022, Novartis received FDA approval for Pluvicto to treat metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen-positive tumors. This approval applies to patients who have previously undergone androgen receptor pathway inhibition and taxane-based chemotherapy. Pluvicto aims to address advanced stages of this specific type of cancer
• In September 2020, Merck presented over 30 abstracts at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, showcasing advancements in oncology research and treatment strategies across various cancers
• In August 2020, Bristol Myers Squibb reported that Idhifa, approved by the FDA for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation, did not demonstrate improved survival outcomes when combined with optimal supportive care in late-stage clinical trials for the same patient group

Cancer Supportive Care Products Market Scope

The market is segmented on the basis of drug class, indication and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Nonsteroidal Anti-Inflammatory Drugs
• Anti-Infective
• Anti-Emetics
• Monoclonal Antibodies
• Erythropoietin Stimulating Agents
• Opioid Analgesics
• Bisphosphonates
• Granulocyte Colony Stimulating Factor

 Indication

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Bladder Cancer
• Leukemia
• Ovary Cancer
• Melanoma Cancer
• Others

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Compounding Pharmacies

Cancer Supportive Care Products Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drug class, indication and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the cancer supportive care products market, driven by biosimilar adoption and higher biologic prices. Increased pharmaceutical R&D will further bolster market growth in the region during the forecast period.

아시아 태평양 지역은 바이오시밀러 채택 증가와 암 유병률 증가로 인해 암 지원 치료 제품 시장에서 상당한 성장을 관찰할 것으로 예상됩니다. 이 지역의 치료 부작용 완화에 대한 집중은 향후 몇 년 동안 예상되는 시장 확장에 기여합니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 암 지원 케어 제품 시장 점유율 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 아카시아 파마 그룹 주식회사(영국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 파그론(벨기에)
•  쿄와핫코바이오(주) (일본)
• APR(스위스)
• F. 호프만-라 로슈 유한회사(스위스)
• 암젠 주식회사(영국)
• 백스터(미국)
• Bayer AG(독일)
• 다이이치 산쿄 주식회사(일본)
• GSK 주식회사(영국)

SKU-10592